Esophageal Cancer
Conditions
Brief summary
This is a prospective observational study designed to observe the toxicity and efficacy of PBS proton RT for patients with esophageal cancer undergoing trimodality therapy. The investigators hypothesize that PBS proton RT will be associated with a favorable adverse event profile and quality of life, with similar disease control outcomes, relative to historical comparisons of patients treated with photon RT.
Interventions
None listed
Sponsors
Mayo Clinic
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years. * Histological confirmation of adenocarcinoma or squamous cell carcinoma of the esophagus (mid, distal, or GE junction) * Stage T1N1-3M0 or T2-4N0-3M0 by American Joint Commission on Cancer (AJCC) 7th edition * Tumor extends ≤ 5 cm into gastric cardia, based on EGD and PET/CT * ECOG Performance Status (PS) 0-2 (Appendix I) * Surgical consultation to confirm that patient is an appropriate candidate for esophagectomy * Medical oncology consultation to confirm that patient is an appropriate candidate for chemotherapy * Planned to receive standard of care neoadjuvant CRT, consisting of PBS proton RT (50 Gy/25 fractions) and concurrent chemotherapy (weekly carboplatin and paclitaxel), followed by surgical resection * Ability to complete questionnaire(s) by themselves or with assistance. * Provide informed written consent. * Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study). Note: During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up. * Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking study, IRB number 15-000136
Exclusion criteria
* Cervical or upper esophageal tumors with any part of tumor \< 24 cm from incisors * Prior chemotherapy or RT for esophageal cancer * History of RT to the thorax * Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of adverse events. * Immunocompromised patients and patients known to be HIV positive and not currently receiving antiretroviral therapy. NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Receiving any investigational agent which would be considered as a treatment for the primary neoplasm. * Other active malignancy ≤ 1 year prior to registration. EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix. NOTE: If there is a history or prior malignancy, they must not be receiving other specific treatment for their cancer. * History of myocardial infarction ≤6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of CTCAE acute grade 3 or higher adverse effects possibly attributed to neoadjuvant CRT | Within 90 days of enrollment |
Secondary
| Measure | Time frame |
|---|---|
| Rate of postoperative complications | Within 30 days following surgery |
| Length of hospital stay | Within 30 days following surgery |
| Rate of CTCAE late grade 3 or higher adverse effects possibly attributed to therapy | 24 months after enrollment |
| Surgical outcomes, including the percentage of patients who undergo a margin-negative (R0) resection and the rate of pathologic complete response (pCR) | Within 30 days following surgery |
| Patient-reported quality of life using LASA-3, Mayo-10, PRO-CTCAE, and FACT-E | 24 months after enrollment |
| Assessment of early cardiac toxicity after CRT using cardiac MRI | 42 days after completion of CRT |
| Rate of local-regional recurrence (LRR), progression-free survival (PFS), and overall survival (OS) | 24 months after enrollment |
Countries
United States
Outcome results
None listed